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Abstract Bis(maltolato)oxovanadium(IV) (BMOV), a protein
phosphotyrosine phosphatase inhibitor, selectively induced apop-
tosis (as quantitated by TUNEL staining) in a B-cell line
(Ramos) but not in a T-cell line (Jurkat). The pattern of BMOV-
induced protein tyrosine phosphorylation was different in B-cells
versus T-cells. Further, BMOV induced a 2-fold increase in
ceramide levels in B-cells but not in T-cells and this resembled the
ceramide increase following activation of the B-cell antigen
receptor. A 2-fold increase in the ratio of ceramide to
sphingomyelin in B-cells treated with BMOV suggested that
sphingomyelinase activation was the result of the sustained
tyrosine phosphorylation of specific proteins and activated the
cell death pathway. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
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1. Introduction
Antigen receptor stimulation in immature B-cells and B-cell
lines leads to cell death by apoptosis [1,2]. Phosphotyrosine
phosphatase-2 (PTP2) is known to downregulate antigen re-
ceptor signalling [3,4], and mice de¢cient in the phosphatase
PTP1C show increased tyrosine phosphorylation and en-
hanced death of self-reactive B-cells [5]. In addition, the radi-
ation-induced cell death of B-lymphocytes involves activation
of protein tyrosine kinases and can be augmented by the PTP
inhibitor vanadate [6]. A selective PTP inhibitor bis(maltola-
to)oxovanadium(IV) (BMOV) induces cell death in B-cells but
not in T-cells [7]. BMOV does not activate the phospholipase
C (PLC) (PLCQ1), involved in T-cell receptor signalling [8], or
any serine or threonine phosphate phosphatases [6,7] but in-
creases tyrosine phosphorylation similar to that seen in signal-
ling via the B-cell receptor [8]. The similarities in mechanism
of action between BMOV and anti-IgM [7] are reinforced by
the observation that B-cells can be rescued from either
BMOV-induced death or B-cell receptor-induced apoptosis
by interleukin-4 plus anti-CD40 antibody treatment [9,10].
However, little is known of the downstream targets of these
B-cell speci¢c tyrosine-phosphorylated proteins.
We have previously shown that B-cell receptor activation
involves sphingomyelinase activation and increased ceramide
(2-N-acetyl sphingosine) formation [11]. Similar increases in
ceramide have been implicated in apoptosis induced by a va-
riety of agents such as TNF-K, Fas, corticosteroids, ionizing
radiation, as well as anti-IgM [11^17]. The apoptosis resulting
from PLCQ2 activation has been suggested to involve IP3/
Ca2 release and diacylglycerol (DAG) formation, leading
to protein kinase C activation, and activation of c-Jun kinase
(JNK) and p38MAPKinase [8], but the precise mechanism is
not known. Since ceramide is known to activate both the
stress kinases such as JNK [18^20] and p38MAPKinase [21],
we investigated whether ceramide levels were elevated by the
phosphatase inhibitor BMOV. We now report that BMOV
induces formation of ceramide in Ramos B-cells but not in
Jurkat T-cells and suggest that increased ceramide formation
is essential for apoptosis in immature B-cells.
2. Materials and methods
2.1. Materials
[1-14C]Palmitoyl CoA (59 mCi/mmol), [32P]orthophosphate (1 Ci/
mmol) were purchased from Amersham Life Science, Arlington
Heights, IL, USA. Ceramide, C2-ceramide and other lipids were pur-
chased from Matreya, Inc. BMOV was synthesized as previously de-
scribed [7].
2.2. Cell culture and FACS analysis
The human B-cell lymphoma line Ramos and the human T-cell
leukemia line Jurkat were obtained from the American Type Culture
Collection and were grown in RPMI 1640 media (Life Technologies,
Inc.) with 10% fetal calf serum [6,7]. Cells were harvested and resus-
pended for cell viability assay by the propidium iodide (PI) exclusion
test as previously described [7,15,16]. For quantitation, cells were run
on a FACScan (Becton-Dickinson, San Jose, CA, USA) and the re-
sults analyzed using Lysis II software as previously described [7,22].
2.3. Detection of tyrosine-phosphorylated proteins
Cellular tyrosine phosphorylation was measured by immunoblot-
ting with a⁄nity-puri¢ed polyclonal rabbit anti-phosphotyrosine anti-
bodies as described previously [7], and antibody binding was detected
by enhanced chemiluminescence (Amersham) in accordance with the
manufacturer’s directions.
2.4. TdT-mediated dUTP-biotin nick end labelling (TUNEL) analysis
of fragmented DNA
TUNEL staining for the in situ detection of fragmented DNA was
carried out as previously described [22]. Following biotin-end terminal
deoxynucleotidyl transferase treatment and detection with £uorescein-
avidin, cells were washed two times in phosphate-bu¡ered saline
(PBS), resuspended in 400 ml of PBS and analyzed using a Becton-
Dickinson FACScan £ow cytometer and Lysis analysis software.
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2.5. Measurement of ceramide
Ceramide and sphingomyelin were labelled by culturing 2U106
cells/£ask for 24 h in media containing 10 WCi [3H]palmitate, the
radioisotope removed by washing and the cells then exposed to
BMOV for 24 or 48 h [11,15]. The extracted lipids [11] were applied
to LHP-K thin layer chromatography (TLC) plates (Whatman)
and developed in chloroform:methanol:glacial acetic acid:water
(85:4.5:5.0:0.5, v/v) to resolve the ceramide doublet from other lipids.
Sphingomyelin was resolved from phosphoglycerides in chloroform:
methanol:glacial acetic acid:water (65:25:8.8:4.5, v/v). Plates were
sprayed with En3Hance (Dupont) and developed overnight with Xo-
mat-AR ¢lm (Kodak) to identify the bands by comparison with au-
thentic standards. Bands were then scraped for liquid scintillation
counting.
Ceramide levels were quanti¢ed by conversion to ceramide
[1-32P]phosphate by Escherichia coli DAG kinase as described previ-
ously [11,13].
3. Results
3.1. The PTP inhibitor BMOV produces di¡erent tyrosine
phosphorylation patterns in B-cells and T-cells
BMOV treatment for 16 h induced a striking increase in
protein tyrosine phosphorylation in Ramos B-cells (Fig.
1A), with a maximum response between 40 and 60 WM.
Some of the proteins showing increased tyrosine phosphory-
lation have previously been identi¢ed as syk (60 kDa) Zap70
kinase (70 kDa) and PLCQ2 (150 kDa). In contrast, treatment
of Jurkat T-cells with 40 WM BMOV induced no increase in
protein tyrosine phosphorylation (Fig. 1B). At 60 WM BMOV,
some increase in phosphorylation was seen in the Jurkat cells
(but not at 60, 70 or 150 kDa) and the pattern was still dis-
tinct from that seen in the Ramos B-cells (Fig. 1A).
3.2. The PTP inhibitor BMOV induces apoptosis in B-cells but
not in T-cells
The increased protein tyrosine phosphorylation induced by
BMOV in Ramos B-cells correlated well with increased cellu-
lar apoptosis in these cells as determined using TUNEL stain-
ing, which recognizes the multiple 3-hydroxy ends of apopto-
tic fragments of DNA. Thus treatment of Ramos B-cells with
25 WM BMOV for 48 h resulted in 70% death and 50 WM
BMOV resulted in 80% cell death (Fig. 2A), whereas a similar
treatment of Jurkat T-cells produced 5% and 25% cell death,
respectively (Fig. 2B).
3.3. BMOV induces cell death and increased ceramide
formation in B-cells
PI stains DNA fragments in cells that have undergone ap-
optosis and lost membrane integrity. Ramos B-cells showed a
dose-dependent increase in both cell death (30% at 50 WM
BMOV for 24 h) (Fig. 3A) and ceramide labelling by
[3H]palmitate (3-fold at 50 WM BMOV for 24 h) (Fig. 3B).
A similar correspondence between cell death and ceramide
formation was observed after 48 h exposure to BMOV, where
the 75% cell death at 40 WM BMOV (Fig. 3C) corresponded
to an average 2-fold increase in ceramide labelling (Fig. 3D).
Quantitation of ceramide levels by the DAG kinase assay
revealed a 1.6-fold increase in ceramide content over basal
levels (80 pmol/mg protein) after treatment of Ramos B-cells
for 24 h with 40 WM BMOV. In contrast, Jurkat T-cells
showed no increase in ceramide over basal at concentrations
up to 60 WM of BMOV for 24 h (data not shown). When
Jurkat T-cells were exposed to the same (50 WM) concentra-
tions of BMOV for 24 h or 48 h, there was little evidence of
cell death by PI staining (Fig. 3A,C) or any signi¢cant in-
crease in the formation of [3H]ceramide (Fig. 3B,D).
3.4. Induction of apoptosis with BMOV increases ceramide,
decreases sphingomyelin and the increase is not blocked by
inhibitors of sphingosine synthesis
Treatment of Ramos B-cells with increasing concentrations
of BMOV led to increased labelling of ceramide relative to
other lipids such as cholesterol (Fig. 4A), corresponding to a
Fig. 1. Induction of cellular tyrosine phosphorylation by BMOV.
Ramos B-cells (A) and Jurkat T-cells (B) were treated 16 h with
BMOV at concentration of 20, 40 and 60 WM. Cellular tyrosine
phosphorylation was detected by anti-phosphotyrosine immunoblots
of whole cell lysate following SDS gel electrophoresis as described
in the text.
Fig. 2. TUNEL analysis of BMOV-treated B-cells and T-cells. Cells were treated with BMOV for 48 h, stained by the TUNEL method and an-
alyzed by £ow cytometry as described in the text. TUNEL analysis was performed without terminal deoxytransferase (TdT) as control (m) and
with TdT on cells treated with 0 WM (9), 25 WM (- - - -) or 50WM (-W-W-) BMOV. A, Ramos B-cells; B, Jurkat T-cells.
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4-fold increase at 80 WM. The ceramide in Ramos B-cells is
predominantly the longer chain form, with C16:0, C22:0, C24:1
and C24:0 fatty acids in the ratio 4:1:4:5. In contrast, in
Jurkat T-cells, the ratio was 6:1:1:1, with palmitate (C16:0)
predominating (data not shown). The ratio of [3H]palmitate
incorporation into ceramide versus that into sphingomyelin
showed a dose-dependent 2.5-fold increase (from 0.08 to
0.22) in Ramos B-cells but not in Jurkat T-cells exposed to
increasing concentrations of BMOV (Fig. 4B).
4. Discussion
Protein PTP inhibitor, BMOV, induced protein phosphor-
ylation changes in Ramos B-cells which were very similar to
those seen after immature B-cell receptor cross-linking [7] and
both resulted in apoptosis. We have previously shown that B-
cell receptor cross-linking is associated with a 4-fold increase
in ceramide and that ceramide was a cause of apoptosis
[11,15]. Further evidence implicating ceramide in apoptosis
is the fact that both exogenous C2- and C6-ceramide induced
apoptosis in B-cells [15] and overexpression of anti-apoptotic
proteins BclxL [11] or Bcl2 [25] conferred resistance to apopto-
sis induced by ceramide. Since the tyrosine phosphorylation
pattern induced by BMOV was di¡erent in B-cells from T-
cells and the increase in ceramide and resulting apoptosis was
only seen in B-cells, it seems likely that this speci¢c tyrosine
phosphorylation is involved in regulating the formation of
ceramide in B-cells.
Ceramide is both a biosynthetic precursor of sphingomyelin
and a product of the action of sphingomyelinase on sphingo-
myelin [17], but several studies have implicated a neutral
sphingomyelinase activity in pro-apoptotic ceramide forma-
tion [12,13,24]. One cloned sphingomyelinase [23] appears to
function as a lyso-PAF-PLC [26] and is localized in Golgi not
plasma membrane [27] so this is probably not the pro-apopto-
tic sphingomyelinase. A second protein, with PLC-type activ-
ity towards sphingomyelin at neutral pH [24], contains a con-
sensus sequence site for protein tyrosine phosphorylation
(238KNRIEHQY) as well as sites for serine and threonine
kinases, suggesting that it could be a candidate for the pro-
apoptotic sphingomyelinase, but this remains to be veri¢ed.
Despite the absence of a clear candidate neutral sphin-
gomyelinase, there is considerable evidence for the activation
of several other PLC-type enzymes by tyrosine phosphoryla-
tion [28], including the PLCQ2 phosphorylated by BMOV,
as well as indirect evidence for the activation of phospholipase
D by tyrosine phosphorylation [29]. Thus, phosphorylation
may be a general mechanism for activating enzymes of this
type.
Fig. 3. Correlation of cell death with ceramide production. Cells
were treated with BMOV for either 24 h (A,B) or 48 h (C,D). A,C:
Induction of cell death by BMOV. Cell death was quantitated by PI
staining as described in the text. B,D: Ceramide was quantitated by
labelling cells with [3H]palmitate, determining the level of ceramide
labelling relative to protein content and expressing this as a percent
of untreated cell ceramide levels.
Fig. 4. Ceramide formation is associated with decreased sphingomyelin. (A) HPTLC separation of [3H]palmitate-labelled lipids. This shows the
increased formation of ceramide (a doublet) compared to other lipids such as cholesterol (Chol) (an increase from 0.09 to 0.36) following treat-
ment of Ramos B-cells with increasing concentrations of BMOV (0^80 WM) for 48 h. (B) The ceramide:sphingomyelin ratio increases with in-
creasing BMOV. Ramos B-cells and Jurkat T-cells were labelled for 24 h with [3H]palmitate and treated with increasing concentrations of
BMOV for 48 h. Lipids were isolated, separated by HPTLC as described in the text, radioactivity determined and the ratio of ceramide to
sphingomyelin calculated.
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